Treatment of idiopathic nephrotic syndrome with two steroid dosing regimens – one-year observational study
Open Access
- 6 October 2021
- journal article
- research article
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
- Vol. 46 (3) , 344-350
Abstract
Introduction: The aim of the study was to compare the first year of disease in children with idiopathic nephrotic syndrome (INS) treated according to two prednisone dosing regimens: a weight-based schedule (2 mg/kg/24 h in the 1st month, 2 mg/kg/48 h in the 2nd month, with dose tapering during the following 4 months), and a body surface area (BSA)-based schedule (60 mg/m2/24 h in the 1st month, 40 mg/m2/48 h in the 2nd month, with dose tapering during the following 4 months). Material and methods: In 2 groups of children treated with weight- and BSA-based regimens (20 patients, 3.13 ±1.01 years, treated in 2010-2013 and 20 patients, 5.13 ±2.86 years, treated in 2014-2016) clinical and anthropometrical parameters, number of INS relapses, total prednisone dose (mg/kg/year), and steroid adverse effects were compared during the first year of disease. Results: Children treated with the weight-based steroid regimen received a higher total annual prednisone dose (259.06 ±79.54 vs. 185.83 ±72.67 mg/kg/24 h, p = 0.004) and had a shorter (though not significantly) period without prednisone (38.25 ±55.83 vs. 75.90 ±73.06 days, p = 0.062) compared to patients treated with the BSA-based regimen. There was no difference in number of relapses between groups (2.20 ±1.64 vs. 1.60 ±1.67, p = 0.190) but more patients relapsed in the weight-based group (19/20 vs. 13/20, p = 0.044). No differences in Z-score values of height, weight, and body mass index (BMI) were observed. No steroid-related adverse events were noted except for arterial hypertension (4/20 vs. 5/20 patients, p = 1.000). Conclusions: The BSA-based regimen of prednisone dosing in children with INS reduces exposure to steroids and risk of relapse, as well as increases days off steroids in the first year compared to the weight-based regimen with a high second-month dose.Keywords
This publication has 24 references indexed in Scilit:
- Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Nephrotic Syndrome in ChildrenAmerican Journal of Kidney Diseases, 2014
- Dosing of glucocorticosteroids in nephrotic syndromePediatric Nephrology, 2011
- Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference?Pediatric Nephrology, 2011
- Prednisone dosing per body weight or body surface area in children with nephrotic syndrome—is it equivalent?Pediatric Nephrology, 2009
- Direct effects of dexamethasone on human podocytesKidney International, 2006
- Dexamethasone Prevents Podocyte Apoptosis Induced by Puromycin AminonucleosideJournal of the American Society of Nephrology, 2005
- Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndromePediatric Nephrology, 1999
- Short versus long initial prednisone treatment in steroid‐sensitive nephrotic syndrome in childrenActa Paediatrica, 1995
- Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosisKidney International, 1978
- THE NEPHROTIC SYNDROMEJAMA, 1957